Genetic, developmental and personality correlates of self-mutilation in depressed patients

Australian and New Zealand Journal of Psychiatry

Volumn 40, Issue 3, 2006, Pages 225-229

  Joyce, Peter R ^a   McKenzie, Janice M ^a   Mulder, Roger T ^a   Luty, Suzanne E ^a   Sullivan, Patrick F ^b   Miller, Allison L ^a   Kennedy, Martin A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Borderline personality disorder; Childhood sexual abuse; Depression; G proteins; Self mutilation

Indexed keywords

FLUOXETINE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT 3; NORTRIPTYLINE; UNCLASSIFIED DRUG;

ADULT; AGE; ALLELE; ARTICLE; AUTOMUTILATION; BORDERLINE STATE; CHILD SEXUAL ABUSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROBIOLOGY; PERSONAL EXPERIENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; ALLELES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BORDERLINE PERSONALITY DISORDER; CHILD; CHILD ABUSE; CHILD ABUSE, SEXUAL; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCOSYLTRANSFERASES; HUMANS; MALE; MULTIVARIATE ANALYSIS; NORTRIPTYLINE; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; SELF MUTILATION; STATISTICS;

EID: 33644910441     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2006.01778.x     Document Type: Article

References (34)

1. Favazza AR. The coming of age of self-mutilation. Journal of Nervous and Mental Disease 1998; 186: 259-268.
2. Briere J, Gil E. Self-mutilation in clinical and general population samples: Prevalence, correlates, and functions. American Journal of Orthopsychiatry 1998; 68: 609-620.
3. Ross S, Heath N. A study of the frequency of self-mutilation in a community sample of adolescents. Journal of Youth and Adolescence 2002; 31: 66-67.
4. Zoroglu SS, Tuzun U, Sar V et al. Suicide attempt and self-mutilation among Turkish high school students in relation with abuse, neglect and dissociation. Psychiatry and Clinical Neurosciences 2003; 57: 119-126.
5. Robey KL, Reck JF, Giacomini KD, Barabas G, Eddey GE. Modes and patterns of self-mutilation in persons with Lesch-Nyhan disease. Developmental Medicine and Child Neurology 2003; 45: 167-171.
6. Iglauer F, Beig C, Dimigen J, et al. Hereditary compulsive self-mutilating behaviour in laboratory rabbits. Laboratory Animals 1995; 29: 385-393.
7. Emslie GJ, Rush AJ, Weinberg WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry 1997; 54: 1031-1037.
8. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL. Fluoxetine in child and adolescent depression: Acute and maintenance treatment. Depression and Anxiety 1998; 7: 32-39.
9. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis. British Medical Journal 1995; 310: 897-901.
10. Joyce PR, Mulder RT, Luty SE et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Australian and New Zealand Journal of Psychiatry 2002; 36: 384-391.
11. Mulder RT, Watkins WG, Joyce PR, Luty SE. Age may affect response to antidepressants with serotonergic and noradrenergic actions. Journal of Affective Disorders 2003; 76: 143-149.
12. Joyce PR, Mulder RT, Luty SE et al. Age dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. International Journal of Neuropsychopharmacology 2003; 6: 339-346.
13. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Sullivan PF, Cloninger CR. Borderline personality disorder in major depression: Symptomatology, temperament, character, differential drug response and six month outcome. Comprehensive Psychiatry 2003; 44: 35-43.
14. Joyce PR, Luty SE, McKenzie JM et al. Bipolar II disorder: Personality and outcome in two clinical samples. Australian and New Zealand Journal of Psychiatry 2004; 38: 433-438.
15. Mulder RT, Joyce PR, Luty SE. The relationship of personality disorders to treatment outcome in depressed outpatients. Journal of Clinical Psychiatry 2003; 64: 259-264.
16. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale, and description. Archives of General Psychiatry 1992; 49: 624-629.
17. Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979; 134: 382-389.
18. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960; 23: 56-62.
19. Parker G, Hadzi-Pavlovic D. Melancholia a disorder of movement and mood. New York: Cambridge University Press, 1996.
20. Spitzer RL, Williams JBW, Gibbon M. Structured clinical interview for dsm-iii-r personality disorders. New York: Biometrics Research Department, New York State Psychiatric Institute, 1987.
21. Parker G, Tupling H, Brown LB. A Parental Bonding Instrument. British Journal of Medical Psychology 1979; 52: 1-10.
22. Joyce PR, McKenzie JM, Luty SE et al. Temperament, childhood environment and psychopathology as risk factors for avoidant and borderline personality disorders. Australian and New Zealand Journal of Psychiatry 2003; 37: 756-764.
23. Newton CR, Graham A, Heptinstall LE et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Research 1989; 17: 2503-2516.
24. Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. New England Journal of Medicine 1999; 340: 1012-1020.
25. Hamm HE. The many faces of G protein signaling. Journal of Biological Chemistry 1998; 273: 669-672.
26. Siffert W. G protein beta3 subunit 825T allele, hypertension, obesity, and diabetic nephropathy. Nephrology, Dialysis, Transplantation 2000; 15: 1298-1306.
27. Siffert W, Rosskopf D, Siffert G et al. Association of a human G-protein beta3 subunit variant with hypertension. Nature Genetics 1998; 18: 45-48.
28. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T Polymorphism of the G protein beta3-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37: 739-743.
29. Bohus M, Limberger M, Ebner U et al. Pain perception during self-reported distress and calmness in patients with borderline personality disorder and self-mutilating behavior. Psychiatry Research 2000; 95: 251-260.
30. Kemperman I, Russ MJ, Clark WC, Kakuma T, Zanine E, Harrison K. Pain assessment in self-injurious patients with borderline personality disorder using signal detection theory. Psychiatry Research 1997; 70: 175-183.
31. Russ MJ, Campbell SS, Kakuma T, Harrison K, Zanine E. EEG theta activity and pain insensitivity in self-injurious borderline patients. Psychiatry Research 1999; 89: 201-214.
32. Herpertz S, Sass H, Favazza A. Impulsivity in self-mutilative behavior: psychometric and biological findings. Journal of Psychiatric Research 1997; 31: 451-465.
33. Steiger H, Koerner N, Engelberg MJ, Israel M, Ng Ying Kin NM, Young SN. Self-destructiveness and serotonin function in bulimia nervosa. Psychiatry Research 2001; 103: 15-26.
34. Florkowski A, Gruszczynski W, Wawrzyniak Z. Selected biochemical parameters of blood serum in soldiers committing self-mutilation. Military Medicine 2001; 166: 375-377.